A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity
Calcium channel blockers are widely used antihypertensives. Mineralocorticoid receptor antagonists are also used to treat hypertension and heart failure. We report here that a number of widely used dihydropyridine class calcium channel blockers are able to inhibit aldosterone-induced activation of m...
Gespeichert in:
| Veröffentlicht in: | Hypertension (Dallas, Tex. 1979) Tex. 1979), 2008-03, Vol.51 (3), p.742-748 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 748 |
|---|---|
| container_issue | 3 |
| container_start_page | 742 |
| container_title | Hypertension (Dallas, Tex. 1979) |
| container_volume | 51 |
| creator | Dietz, Jessica D Du, Sarah Bolten, Charles W Payne, Maria A Xia, Chunsheng Blinn, James R Funder, John W Hu, Xiao |
| description | Calcium channel blockers are widely used antihypertensives. Mineralocorticoid receptor antagonists are also used to treat hypertension and heart failure. We report here that a number of widely used dihydropyridine class calcium channel blockers are able to inhibit aldosterone-induced activation of mineralocorticoid receptor. These dihydropyridines varied in the extent of their effect on mineralocorticoid receptor, with nimodipine and felodipine the most potent and amlodipine the least. In contrast, both diltiazem and verapamil, nondihydropyridine calcium channel blockers, had no effect on mineralocorticoid receptor. These dihydropyridines compete with aldosterone for binding and block aldosterone-induced coactivator recruitment to mineralocorticoid receptor. The mineralocorticoid receptor S810L mutant, which is activated by steroidal mineralocorticoid receptor antagonist such as eplerenone, is inhibited by these drugs. Furthermore, nimodipine decreased aldosterone-induced expression of the mineralocorticoid receptor target gene epithelial sodium channel gamma subunit in adrenalectomized rats, demonstrating that dihydropyridine calcium channel blockers can function as mineralocorticoid receptor antagonists in vivo. Molecular modeling indicates that dihydropyridines dock into the ligand binding domain of mineralocorticoid receptor in a consensus pose that partially overlaps with steroidal mineralocorticoid receptor antagonists. Together, our data suggest that, in addition to their calcium channel blocking activity, a number of dihydropyridine calcium channel blockers also have mineralocorticoid receptor antagonist activity at high doses, a finding which may thus prove useful for the design of novel antihypertensive drugs in the future. |
| doi_str_mv | 10.1161/HYPERTENSIONAHA.107.103580 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70321486</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20587704</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6079-4d85554789a69f81154b8c10f3d0b8013c335d185f058a8ac19837279cffc2bd3</originalsourceid><addsrcrecordid>eNqFkU1vEzEQhi0EoqHwF5CFBLctHn-svdyWkDaV2hSVIsFp5Xi9xGR3ndreVvn3GCUCiQsjjUYePeP38CD0BsgZQAnvl98_L27vFqsvlzerelmfAZG5mVDkCZqBoLzgomRP0YxAxYsK4NsJehHjT0KAcy6foxNQVBBW8hm6r_FqGtY2YN_hax22NtkWf3KbfRv8bh9c60aL57o3bhrwfKPH0fb4Y-_N1oaIl_rB4uuMBJ1XPiRnvGvxrTV2l3zA9Zj0Dz-6mHBtkntwaf8SPet0H-2r4zxFX88Xd_NlcXVzcTmvrwpTElkVvFVCCC5VpcuqUwCCr5UB0rGWrBUBZhgTLSjREaG00gYqxSSVlek6Q9ctO0XvDv_ugr-fbEzN4KKxfa9H66fYSMIocFX-F6Q5QErCM_jhAJrgYwy2a3bBDTrsGyDNbzPNP2byXjYHM_n49TFlWg-2_Xt6VJGBt0dAR6P7LujRuPiHowQoYwoyxw_co-9TdrDtp0cbmo3Vfdo0JBenpSooITk1v4rctGK_AGDgqLY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20587704</pqid></control><display><type>article</type><title>A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Dietz, Jessica D ; Du, Sarah ; Bolten, Charles W ; Payne, Maria A ; Xia, Chunsheng ; Blinn, James R ; Funder, John W ; Hu, Xiao</creator><creatorcontrib>Dietz, Jessica D ; Du, Sarah ; Bolten, Charles W ; Payne, Maria A ; Xia, Chunsheng ; Blinn, James R ; Funder, John W ; Hu, Xiao</creatorcontrib><description>Calcium channel blockers are widely used antihypertensives. Mineralocorticoid receptor antagonists are also used to treat hypertension and heart failure. We report here that a number of widely used dihydropyridine class calcium channel blockers are able to inhibit aldosterone-induced activation of mineralocorticoid receptor. These dihydropyridines varied in the extent of their effect on mineralocorticoid receptor, with nimodipine and felodipine the most potent and amlodipine the least. In contrast, both diltiazem and verapamil, nondihydropyridine calcium channel blockers, had no effect on mineralocorticoid receptor. These dihydropyridines compete with aldosterone for binding and block aldosterone-induced coactivator recruitment to mineralocorticoid receptor. The mineralocorticoid receptor S810L mutant, which is activated by steroidal mineralocorticoid receptor antagonist such as eplerenone, is inhibited by these drugs. Furthermore, nimodipine decreased aldosterone-induced expression of the mineralocorticoid receptor target gene epithelial sodium channel gamma subunit in adrenalectomized rats, demonstrating that dihydropyridine calcium channel blockers can function as mineralocorticoid receptor antagonists in vivo. Molecular modeling indicates that dihydropyridines dock into the ligand binding domain of mineralocorticoid receptor in a consensus pose that partially overlaps with steroidal mineralocorticoid receptor antagonists. Together, our data suggest that, in addition to their calcium channel blocking activity, a number of dihydropyridine calcium channel blockers also have mineralocorticoid receptor antagonist activity at high doses, a finding which may thus prove useful for the design of novel antihypertensive drugs in the future.</description><identifier>ISSN: 0194-911X</identifier><identifier>EISSN: 1524-4563</identifier><identifier>DOI: 10.1161/HYPERTENSIONAHA.107.103580</identifier><identifier>PMID: 18250364</identifier><identifier>CODEN: HPRTDN</identifier><language>eng</language><publisher>Philadelphia, PA: American Heart Association, Inc</publisher><subject>Adrenalectomy ; Aldosterone - metabolism ; Animals ; Antihypertensive agents ; Arterial hypertension. Arterial hypotension ; Biological and medical sciences ; Blood and lymphatic vessels ; Calcium Channel Blockers - pharmacology ; Cardiology. Vascular system ; Cardiovascular system ; Dihydropyridines - pharmacology ; Dose-Response Relationship, Drug ; Epithelial Sodium Channels - metabolism ; Male ; Medical sciences ; Mineralocorticoid Receptor Antagonists ; Models, Molecular ; Mutation ; Nimodipine - pharmacology ; Pharmacology. Drug treatments ; Protein Binding ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; Receptors, Mineralocorticoid - genetics ; Receptors, Mineralocorticoid - metabolism</subject><ispartof>Hypertension (Dallas, Tex. 1979), 2008-03, Vol.51 (3), p.742-748</ispartof><rights>2008 American Heart Association, Inc.</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6079-4d85554789a69f81154b8c10f3d0b8013c335d185f058a8ac19837279cffc2bd3</citedby><cites>FETCH-LOGICAL-c6079-4d85554789a69f81154b8c10f3d0b8013c335d185f058a8ac19837279cffc2bd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3674,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20123381$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18250364$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dietz, Jessica D</creatorcontrib><creatorcontrib>Du, Sarah</creatorcontrib><creatorcontrib>Bolten, Charles W</creatorcontrib><creatorcontrib>Payne, Maria A</creatorcontrib><creatorcontrib>Xia, Chunsheng</creatorcontrib><creatorcontrib>Blinn, James R</creatorcontrib><creatorcontrib>Funder, John W</creatorcontrib><creatorcontrib>Hu, Xiao</creatorcontrib><title>A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity</title><title>Hypertension (Dallas, Tex. 1979)</title><addtitle>Hypertension</addtitle><description>Calcium channel blockers are widely used antihypertensives. Mineralocorticoid receptor antagonists are also used to treat hypertension and heart failure. We report here that a number of widely used dihydropyridine class calcium channel blockers are able to inhibit aldosterone-induced activation of mineralocorticoid receptor. These dihydropyridines varied in the extent of their effect on mineralocorticoid receptor, with nimodipine and felodipine the most potent and amlodipine the least. In contrast, both diltiazem and verapamil, nondihydropyridine calcium channel blockers, had no effect on mineralocorticoid receptor. These dihydropyridines compete with aldosterone for binding and block aldosterone-induced coactivator recruitment to mineralocorticoid receptor. The mineralocorticoid receptor S810L mutant, which is activated by steroidal mineralocorticoid receptor antagonist such as eplerenone, is inhibited by these drugs. Furthermore, nimodipine decreased aldosterone-induced expression of the mineralocorticoid receptor target gene epithelial sodium channel gamma subunit in adrenalectomized rats, demonstrating that dihydropyridine calcium channel blockers can function as mineralocorticoid receptor antagonists in vivo. Molecular modeling indicates that dihydropyridines dock into the ligand binding domain of mineralocorticoid receptor in a consensus pose that partially overlaps with steroidal mineralocorticoid receptor antagonists. Together, our data suggest that, in addition to their calcium channel blocking activity, a number of dihydropyridine calcium channel blockers also have mineralocorticoid receptor antagonist activity at high doses, a finding which may thus prove useful for the design of novel antihypertensive drugs in the future.</description><subject>Adrenalectomy</subject><subject>Aldosterone - metabolism</subject><subject>Animals</subject><subject>Antihypertensive agents</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Calcium Channel Blockers - pharmacology</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular system</subject><subject>Dihydropyridines - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Epithelial Sodium Channels - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mineralocorticoid Receptor Antagonists</subject><subject>Models, Molecular</subject><subject>Mutation</subject><subject>Nimodipine - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Binding</subject><subject>Random Allocation</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, Mineralocorticoid - genetics</subject><subject>Receptors, Mineralocorticoid - metabolism</subject><issn>0194-911X</issn><issn>1524-4563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1vEzEQhi0EoqHwF5CFBLctHn-svdyWkDaV2hSVIsFp5Xi9xGR3ndreVvn3GCUCiQsjjUYePeP38CD0BsgZQAnvl98_L27vFqsvlzerelmfAZG5mVDkCZqBoLzgomRP0YxAxYsK4NsJehHjT0KAcy6foxNQVBBW8hm6r_FqGtY2YN_hax22NtkWf3KbfRv8bh9c60aL57o3bhrwfKPH0fb4Y-_N1oaIl_rB4uuMBJ1XPiRnvGvxrTV2l3zA9Zj0Dz-6mHBtkntwaf8SPet0H-2r4zxFX88Xd_NlcXVzcTmvrwpTElkVvFVCCC5VpcuqUwCCr5UB0rGWrBUBZhgTLSjREaG00gYqxSSVlek6Q9ctO0XvDv_ugr-fbEzN4KKxfa9H66fYSMIocFX-F6Q5QErCM_jhAJrgYwy2a3bBDTrsGyDNbzPNP2byXjYHM_n49TFlWg-2_Xt6VJGBt0dAR6P7LujRuPiHowQoYwoyxw_co-9TdrDtp0cbmo3Vfdo0JBenpSooITk1v4rctGK_AGDgqLY</recordid><startdate>200803</startdate><enddate>200803</enddate><creator>Dietz, Jessica D</creator><creator>Du, Sarah</creator><creator>Bolten, Charles W</creator><creator>Payne, Maria A</creator><creator>Xia, Chunsheng</creator><creator>Blinn, James R</creator><creator>Funder, John W</creator><creator>Hu, Xiao</creator><general>American Heart Association, Inc</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>200803</creationdate><title>A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity</title><author>Dietz, Jessica D ; Du, Sarah ; Bolten, Charles W ; Payne, Maria A ; Xia, Chunsheng ; Blinn, James R ; Funder, John W ; Hu, Xiao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6079-4d85554789a69f81154b8c10f3d0b8013c335d185f058a8ac19837279cffc2bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adrenalectomy</topic><topic>Aldosterone - metabolism</topic><topic>Animals</topic><topic>Antihypertensive agents</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Calcium Channel Blockers - pharmacology</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular system</topic><topic>Dihydropyridines - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Epithelial Sodium Channels - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mineralocorticoid Receptor Antagonists</topic><topic>Models, Molecular</topic><topic>Mutation</topic><topic>Nimodipine - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Binding</topic><topic>Random Allocation</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, Mineralocorticoid - genetics</topic><topic>Receptors, Mineralocorticoid - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dietz, Jessica D</creatorcontrib><creatorcontrib>Du, Sarah</creatorcontrib><creatorcontrib>Bolten, Charles W</creatorcontrib><creatorcontrib>Payne, Maria A</creatorcontrib><creatorcontrib>Xia, Chunsheng</creatorcontrib><creatorcontrib>Blinn, James R</creatorcontrib><creatorcontrib>Funder, John W</creatorcontrib><creatorcontrib>Hu, Xiao</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dietz, Jessica D</au><au>Du, Sarah</au><au>Bolten, Charles W</au><au>Payne, Maria A</au><au>Xia, Chunsheng</au><au>Blinn, James R</au><au>Funder, John W</au><au>Hu, Xiao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity</atitle><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle><addtitle>Hypertension</addtitle><date>2008-03</date><risdate>2008</risdate><volume>51</volume><issue>3</issue><spage>742</spage><epage>748</epage><pages>742-748</pages><issn>0194-911X</issn><eissn>1524-4563</eissn><coden>HPRTDN</coden><abstract>Calcium channel blockers are widely used antihypertensives. Mineralocorticoid receptor antagonists are also used to treat hypertension and heart failure. We report here that a number of widely used dihydropyridine class calcium channel blockers are able to inhibit aldosterone-induced activation of mineralocorticoid receptor. These dihydropyridines varied in the extent of their effect on mineralocorticoid receptor, with nimodipine and felodipine the most potent and amlodipine the least. In contrast, both diltiazem and verapamil, nondihydropyridine calcium channel blockers, had no effect on mineralocorticoid receptor. These dihydropyridines compete with aldosterone for binding and block aldosterone-induced coactivator recruitment to mineralocorticoid receptor. The mineralocorticoid receptor S810L mutant, which is activated by steroidal mineralocorticoid receptor antagonist such as eplerenone, is inhibited by these drugs. Furthermore, nimodipine decreased aldosterone-induced expression of the mineralocorticoid receptor target gene epithelial sodium channel gamma subunit in adrenalectomized rats, demonstrating that dihydropyridine calcium channel blockers can function as mineralocorticoid receptor antagonists in vivo. Molecular modeling indicates that dihydropyridines dock into the ligand binding domain of mineralocorticoid receptor in a consensus pose that partially overlaps with steroidal mineralocorticoid receptor antagonists. Together, our data suggest that, in addition to their calcium channel blocking activity, a number of dihydropyridine calcium channel blockers also have mineralocorticoid receptor antagonist activity at high doses, a finding which may thus prove useful for the design of novel antihypertensive drugs in the future.</abstract><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>American Heart Association, Inc</pub><pmid>18250364</pmid><doi>10.1161/HYPERTENSIONAHA.107.103580</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0194-911X |
| ispartof | Hypertension (Dallas, Tex. 1979), 2008-03, Vol.51 (3), p.742-748 |
| issn | 0194-911X 1524-4563 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70321486 |
| source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | Adrenalectomy Aldosterone - metabolism Animals Antihypertensive agents Arterial hypertension. Arterial hypotension Biological and medical sciences Blood and lymphatic vessels Calcium Channel Blockers - pharmacology Cardiology. Vascular system Cardiovascular system Dihydropyridines - pharmacology Dose-Response Relationship, Drug Epithelial Sodium Channels - metabolism Male Medical sciences Mineralocorticoid Receptor Antagonists Models, Molecular Mutation Nimodipine - pharmacology Pharmacology. Drug treatments Protein Binding Random Allocation Rats Rats, Sprague-Dawley Receptors, Mineralocorticoid - genetics Receptors, Mineralocorticoid - metabolism |
| title | A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T01%3A43%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Number%20of%20Marketed%20Dihydropyridine%20Calcium%20Channel%20Blockers%20Have%20Mineralocorticoid%20Receptor%20Antagonist%20Activity&rft.jtitle=Hypertension%20(Dallas,%20Tex.%201979)&rft.au=Dietz,%20Jessica%20D&rft.date=2008-03&rft.volume=51&rft.issue=3&rft.spage=742&rft.epage=748&rft.pages=742-748&rft.issn=0194-911X&rft.eissn=1524-4563&rft.coden=HPRTDN&rft_id=info:doi/10.1161/HYPERTENSIONAHA.107.103580&rft_dat=%3Cproquest_cross%3E20587704%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20587704&rft_id=info:pmid/18250364&rfr_iscdi=true |